Utah Medical Products Inc.
UTMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for UTMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · UTMD
Utah Medical Products Inc. (UTMD) is a medical device company focused on developing and manufacturing specialty products for the healthcare industry, with a strong balance sheet and ongoing clinical trials for novel treatments.
Key risk: Trade policy impact
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 8 clinical trials · 2 catalysts for Utah Medical Products Inc..
Utah Medical Products Inc. (UTMD) is a medical device company focused on developing and manufacturing specialty products for the healthcare industry, with a strong balance sheet and ongoing clinical trials for novel treatments.
- Cash & equivalents of $87.5M as of 2026-06-30 [sec].
- Total revenue of $8.5M as of 2026-06-30 [sec].
- Shareholders' equity of $119.3M as of 2026-06-30 [sec].
- Total debt of $0.2M as of 2026-06-30 [sec].
- Plans to introduce high-pressure process control transducer configurations directly to biopharmaceutical manufacturers [sec_mda · as of 2026-03-27].
What works
- Strong financial position with $87.5M cash and minimal debt of $0.2M as of 2026-06-30 [sec].
- Positive cash generation supports dividends and share repurchases when management deems shares undervalued [sec_mda · as of 2026-03-27].
- Ongoing product development and expansion into biopharmaceutical transducer market [sec_mda · as of 2026-03-27].
What to weigh
- Loss of largest distributor for blood pressure monitoring devices in China in 3Q 2025 impacted financial results [sec_mda · as of 2026-05-12].
- OUS business hindered by recent U.S. government trade policies [sec_mda · as of 2026-03-27].
- Pending Filshie Clip System product liability lawsuits in the U.S. [sec_mda · as of 2026-03-27].
From the filings
Quoted directly from source documents.
Plans to regain OUS business hindered by trade policies
“regain OUS business which has been hindered by recent U.S. government trade policies”
SEC MD&A · March 27, 2026
Loss of largest distributor in China
“The major projected change in 1Q 2026 financial results had to do with the 3Q 2025 loss of UTMD's largest distributor for blood pressure monitoring devices located in China.”
SEC MD&A · May 12, 2026
Filshie Clip System lawsuits
“substantially bring the Filshie Clip System product liability lawsuits in the U.S. to a favorable conclusion”
SEC MD&A · March 27, 2026
Catalyst timeline
- 2031-04-01 · Phase3_Topline — Phase 3 Topline: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus — Topline results from a Phase 3 trial evaluating a paclitaxel-coated balloon for esophageal stricture.
- 2032-12-31 · Phase3_Topline — Phase 3 Topline: Randomized Controlled Clinical Trial (RCT) of the Nectero EAST System for Small to Mid-Sized Abdomin — Topline results from a Phase 3 RCT of the Nectero EAST System for small to mid-sized abdominal aortic aneurysms.
Risks & what to watch (3)›
Key risks
- Trade policy impact — OUS business hindered by U.S. government trade policies [sec_mda · as of 2026-03-27]
- Distributor loss in China — Loss of largest distributor for blood pressure monitoring devices in China in 3Q 2025 [sec_mda · as of 2026-05-12]
- Product liability lawsuits — Pending Filshie Clip System product liability lawsuits in the U.S. [sec_mda · as of 2026-03-27]
What to watch
- Progress on new sales of high-pressure process control transducer configurations to biopharmaceutical manufacturers [sec_mda · as of 2026-03-27].
- Resolution of Filshie Clip System product liability lawsuits [sec_mda · as of 2026-03-27].
- Impact of U.S. trade policies on OUS business recovery [sec_mda · as of 2026-03-27].
- Phase 3 topline results for Paclitaxel Coated Balloon (expected 2031-04-01) and Nectero EAST System (expected 2032-12-31) [catalyst].
Sources: Catalysts · Competitor trials · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Utah Medical Products Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Utah Medical Products Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.02 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~1675d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
119
Total value held
$140.9M
| Holder | Shares | Value |
|---|---|---|
| brandes investment partners, lp | 449,279 | $27.9M |
| vanguard capital management llc | 277,120 | $17.2M |
| dimensional fund advisors lp | 197,908 | $12.3M |
| blackrock, inc. | 187,649 | $11.6M |
| renaissance technologies llc | 184,114 | $11.4M |
| geode capital management, llc | 120,097 | $7.4M |
| hotchkis & wiley capital management llc | 89,131 | $5.5M |
| rice hall james & associates, llc | 67,882 | $4.2M |
| state street corp | 64,402 | $4.0M |
| morgan stanley | 48,801 | $3.0M |
Showing top 10 of 119 institutional holders of Utah Medical Products Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 5.3%
- Days to cover
- 9.4
- Shares short
- 137,091
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
UTMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Utah Medical Products Inc.?
Utah Medical Products Inc. (UTMD) is a medical device company focused on developing and manufacturing specialty products for the healthcare industry, with a strong balance sheet and ongoing clinical trials for novel treatments.
What is Utah Medical Products Inc.'s next catalyst?
Utah Medical Products Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus" — expected April 1, 2031.
Who is the CEO of Utah Medical Products Inc.?
Mr. Kevin L. Cornwell is the chief executive officer of Utah Medical Products Inc. (UTMD).
Where is Utah Medical Products Inc. headquartered?
Utah Medical Products Inc. (UTMD) is headquartered in Midvale, UT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.